Newer paradigms in renal replacement therapy: Will they alter cardiovascular outcomes?

Cardiology Clinics

Volumn 23, Issue 3, 2005, Pages 385-391

  Kundhal, Kiran ^a   Pierratos, Andreas ^b   Chan, Christopher T ^a  

^a TORONTO GENERAL HOSPITAL   (Canada)

^b HUMBER RIVER REGIONAL HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM; HOMOCYSTEINE; LIPID; PARATHYROID HORMONE; PHOSPHATE;

BLOOD PRESSURE; BLOOD PRESSURE REGULATION; CALCIUM METABOLISM; CARDIOVASCULAR DISEASE; CARDIOVASCULAR EFFECT; CARDIOVASCULAR PARAMETERS; CARDIOVASCULAR RISK; GEOMETRY; HEART LEFT VENTRICLE CONTRACTION; HEART RATE; HEMODIALYSIS; HOME DIALYSIS; HORMONE DETERMINATION; HUMAN; HYPERPARATHYROIDISM; HYPOXEMIA; KIDNEY DISEASE; KIDNEY TRANSPLANTATION; METABOLISM; MORBIDITY; MORTALITY; PATIENT; PHOSPHATE METABOLISM; PRIORITY JOURNAL; REVIEW; SLEEP APNEA SYNDROME; SURVIVAL; SYSTOLE;

ANOXEMIA; CARDIOVASCULAR DISEASES; HUMANS; HYPERHOMOCYSTEINEMIA; HYPERLIPIDEMIAS; HYPERPARATHYROIDISM, SECONDARY; KIDNEY FAILURE, CHRONIC; RENAL DIALYSIS; SLEEP APNEA SYNDROMES; TREATMENT OUTCOME;

EID: 23244455121     PISSN: 07338651     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ccl.2005.03.001     Document Type: Review

References (77)

1. R.N. Foley, P.S. Parfrey, and M.J. Arnak Clinial epidemiology of cardiovascular disease in chronic renal disease Am J Kidney Dis 32 1998 S112 S119
2. G.M. London, A.P. Guerin, and S.J. Marchais Cardiac and arterial interactions in end-stage renal disease Kidney Int 50 1996 600 608
3. C. Zoccali, F. Mallamaci, and G. Tripepi Traditional and emerging cardiovascular risk factors in end-stage renal disease Kidney Int Suppl 85 2003 105 110
4. S. Verma, and T.J. Anderson Fundamentals of endothelial function for the clinical cardiologist Circulation 105 2002 546 549
5. B. Pannier, A.P. Guerin, and S. Marchais Postischemic vasodilation, endothelial activation, and cardiovascular remodeling in end-stage renal disease Kidney Int 57 2000 1091 1099
6. G.E. McVeigh, G.M. Brennan, and G.D. Johnston Impaired endothelium-dependent and independent vasodilation in patients with type 2 (non-insulin-dependent) diabetes mellitus Diabetologia 35 1992 771 776
7. J.A. Panza, P.R. Casino, and C.M. Kilcoyne Role of endothelium-derived nitric oxide in the abnormal endothelium-dependent vascular relaxation of patients with essential hypertension Circulation 87 1993 1468 1474
8. C. Seiler, O.M. Hess, and M. Buechi Influence of serum cholesterol and other coronary risk factors on vasomotion of angiographically normal coronary arteries Circulation 88 1993 2139 2148
9. R. Fathi, B. Haluska, and N. Isbel The relative importance of vascular structure and function in predicting cardiovascular events J Am Coll Cardiol 43 2004 616 623
10. J.M. Lopez-Gomez, E. Verde, and R. Perez-Garcia Blood pressure, left ventricular hypertrophy and long-term prognosis in hemodialysis patients Kidney Int Suppl 68 1998 S92 S98
11. W.F. Owen Jr., G.M. Chertow, and J.M. Lazarus Dose of hemodialysis and survival: differences by race and sex JAMA 280 1998 1764 1768
12. R.N. Foley, P.S. Parfrey, and J.D. Harnett The prognostic importance of left ventricular geometry in uremic cardiomyopathy J Am Soc Nephrol 5 1995 2024 2031
13. R.N. Foley, P.S. Parfrey, and G.M. Kent Serial change in echocardiographic parameters and cardiac failure in end-stage renal disease J Am Soc Nephrol 11 2000 912 916
14. G.A. Block, T.E. Hulbert-Shearon, and N.W. Levin Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: a national study Am J Kidney Dis 31 1998 607 617
15. G.M. London Vascular disease and atherosclerosis in uremia Blood Purif 19 2001 139 142
16. O.S. Indridason, and L.D. Quarles Hyperphosphatemia in end-stage renal disease Adv Ren Replace Ther 9 2002 184 192
17. K. Amann, E. Ritz, and G. Wiest A role of parathyroid hormone for the activation of cardiac fibroblasts in uremia J Am Soc Nephrol 4 1994 1814 1819
18. J.R. DePalma, E.A. Pecker, and A. Gordon A new compact automatic home hemodialysis system Trans Am Soc Artif Intern Organs 14 1968 152 159
19. R. Uldall, M. Ouwendyk, and R. Francoeur Slow nocturnal home hemodialysis at the Wellesley Hospital Adv Ren Replace Ther 3 1996 133 136
20. W.R. Clark, J.K. Leypoldt, and L.W. Henderson Quantifying the effect of changes in the hemodialysis prescription of effective solute removal with a mathematical model J Am Soc Nephrol 10 3 1999 601 609
21. A.S. Goldfarb-Rumyantzev, A.K. Cheung, and J.K. Leypoldt Computer simulation of small-solute and middle-molecule removal during short daily and long thrice-weekly hemodialysis Am J Kidney Dis 40 6 2002 1211 1218
22. A. Pierratos Effect of therapy time and frequency on effective solute removal Semin Dial 14 4 2001 284 288
23. J.K. Leypoldt, A.K. Cheung, and C.E. Carroll Effect of dialysis membranes and middle molecule removal on chronic hemodialysis patient survival Am J Kidney Dis 33 2 1999 349 355
24. A.K. Cheung, N.W. Levin, and T. Greene Effects of high-flux hemodialysis and clinical outcomes: results of the HEMO study J Am Soc Nephrol 14 12 2003 3251 3263
25. J.E. Brissenden, A. Pierratos, and M. Ouwendyk Improvements in quality of life with nocturnal hemodialysis J Am Soc Nephrol 9 1998 168A
26. M.P. Kooistra, J. Vos, and H.A. Koomans Daily home hemodialysis in the Netherlands: effects of metabolic control, haemodynamics, and quality of life Nephrol Dial Transplant 13 11 1998 2853 2860
27. J.D. Woods, F.K. Port, and S. Orzol Clinical and biochemical correlates of starting "daily" hemodialysis Kidney Int 55 6 1999 2467 2476
28. G.O. Ting, C. Kjellstrand, and T. Freitas Long-term study of high-comorbidity ESRD patients converted from conventional to short daily hemodialysis Am J Kidney Dis 42 5 2003 1020 1035
29. D. Schwartz, A. Pierratos, and R.M.A. Richardson Impact of nocturnal home hemodialysis on anemia management in patients with end-stage renal disease Clin Nephrol 63 2005 202 208
30. P.J. Hanly, and A. Pierratos Improvement of sleep apnea in patients with chronic renal failure who undergo nocturnal hemodialysis N Engl J Med 344 2 2001 102 107
31. P.A. McFarlane, A. Pierratos, and D.A. Redelemeier Cost savings of home nocturnal versus conventional in-center hemodialysis Kidney Int 62 6 2002 2216 2222
32. A. Kroeker, W.F. Clark, and A.P. Heidenheim An operating cost comparison between conventional and home quotidian hemodialysis Am J Kidney Dis 41 1 Suppl 2003 49 55
33. M.P. Horl, and W.H. Horl Hemodialysis-associated hypertension: pathophysiology and therapy Am J Kidney Dis 39 2002 227 244
34. G.M. London Cardiovascular disease in chronic renal failure: pathophysiologic aspects Semin Dial 16 2003 85 94
35. R.L. Lins, M. Elseviers, and P. Rogiers Importance of volume factors in dialysis related hypertension Clin Nephrol 48 1997 29 33
36. G. Onesti, K.E. Kim, and J.A. Greco Blood pressure regulation in end-stage renal disease and anephric man Circ Res 36 1975 145 152
37. J.D. Woods, F.K. Port, and S. Orzol Clinical and biochemical correlates of starting "daily" hemodialysis Kidney Int 55 1999 2467 2476
38. R.M. Fagugli, G. Reboldi, and G. Quintaliani Short daily hemodialysis: blood pressure control and left ventricular mass reduction in hypertensive hemodialysis patients Am J Kidney Dis 38 2001 371 376
39. D.S. Raj, B. Charra, and A. Pierratos In search of ideal hemodialysis: is prolonged frequent dialysis the answer Am J Kidney Dis 34 1999 597 610
40. C.T. Chan, J.S. Floras, and J.A. Miller Regression of left ventricular hypertrophy after conversion to nocturnal hemodialysis Kidney Int 61 2002 2235 2239
41. G. Nesrallah, R. Suri, and L. Moist Volume control and blood pressure management in patients undergoing quotidian hemodialysis Am J Kidney Dis 41 1 Suppl 2003 13 17
42. C.T. Chan, P.J. Harvey, and P. Picton Short-term blood pressure, noradrenergic, and vascular effects of nocturnal home hemodialysis Hypertension 42 2003 925 931
43. M. Chaigon, W.T. Chen, and R.C. Tarazi Effect of hemodialysis on blood volume distribution and cardiac output Hypertension 3 1981 327 332
44. C. Zoccali, F. Mallamaci, and F.A. Benedetto Cardiac natriuretic peptides are related to left ventricular mass and function and predict mortality in dialysis patients J Am Soc Nephrol 12 2001 1508 1515
45. G. London, A. Guerin, and B. Pannier Increased systolic pressure in chronic uremia. Role of arterial wave reflections Hypertension 20 1992 10 19
46. P.S. Klassen, E.G. Lowrie, and D.N. Reddan Association between pulse pressure and mortality in patients undergoing maintenance hemodialysis JAMA 287 2002 1548 1555
47. G.M. London, A.P. Guerin, and S.J. Marchais Cardiac and arterial interactions in end-stage renal disease Kidney Int 50 1996 600 608
48. A.M. Katz Cardiomyopathy of overload. A major determinant of prognosis in congestive heart failure N Engl J Med 322 1990 100 110
49. J.J. Atherton, T.D. Moore, and S.S. Lele Diastolic ventricular interaction in chronic heart failure Lancet 349 1997 1720 1724
50. C.T. Chan, J.S. Floras, and J.A. Miller Improvement in ejection fraction by nocturnal hemodialysis in end-stage renal failure patients with coexisting heart failure Nephrol Dial Transplant 17 2002 1518 1521
51. T. Gordon, W. Castelli, and M. Hjortland High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study Am J Med 62 1977 707 714
52. W. Castelli Cardiovascular disease and multifactorial risk: challenge of the 1980s Am Heart J 106 5 Pt 2 1983 1191 1200
53. J. Hokanson, and M. Austin Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: a meta-analysis of population-based prospective studies J Cardiovasc Risk 3 1996 213 219
54. J. Jeppesen, H. Hein, and P. Suadicani Triglyceride concentration and ischemic heart disease: an eight-year follow-up in the Copenhagen Male Study Circulation 97 1998 1029 1036
55. C. Wanner Importance of hyperlipidemia and therapy in renal patients Nephrol Dial Transplant 15 Suppl 5 2000 92 96
56. T. Shoji, Y. Nishizawa, and T. Kawagishi Atherogenic lipoprotein changes in the absence of hyperlipidemia in patients with chronic renal failure treated by hemodialysis Atherosclerosis 131 1997 229 236
57. P. Attman, O. Samuelsson, and P. Alaupovic Lipoprotein metabolism and renal failure Am J Kidney Dis 21 1993 573 592
58. A.L. Bugeja, and C.T. Chan Improvement in lipid profile by nocturnal hemodialysis in patients with end-stage renal disease ASAIO J 40 2004 1 4
59. G.A. Block, T.E. Hulbert-Shearon, and N.W. Levin Association of serum phosphors and calcium x phosphate product with mortality risk in chronic hemodialysis patients: a national study Am J Kidney Dis 31 4 1998 607 617
60. C.A. DeSoi, and J.G. Umans Phosphate kinetics during high-flux hemodialysis J Am Soc Nephrol 4 5 1993 1214 1218
61. Mucsi I, Hercz G, Uldall R, et al. Control of serum phosphate without any phosphate binders in patients treated with nocturnal hemodialysis. Kidney Int 53(5):1399-1404.
62. S.J. Kim, M. Goldstein, and T. Szabo Resolution of massive uremic tumoral calcinosis with daily nocturnal home hemodialysis Am J Kidney Dis 41 3 2003 E12
63. A. Pierratos, G. Hercz, and D.J. Sherrard Calcium, phosphorus metabolism and bone pathology on long term nocturnal hemodialysis J Am Soc Nephrol 12 2001 274A
64. F. Al Hejaili, C. Kortas, and R. Leitch Nocturnal but not short hours quotidian hemodialysis requires an elevated dialysate calcium concentration J Am Soc Nephrol 14 9 2003 2322 2328
65. A.N. Friedman, A.G. Bostom, and A.S. Levey Plasma total homocysteine levels among patients undergoing nocturnal versus standard hemodialysis J Am Soc Nephrol 13 1 2002 265 268
66. G. Nesrallah, R. Suri, and L. Moist Volume control and blood pressure management in patients undergoing quotidian hemodialysis Am J Kidney Dis 42 1 Suppl 2003 13 17
67. C. Zoccali, F.A. Benedetto, and F. Mallamaci Left ventricular hypertrophy and nocturnal hypoxemia in hemodialysis patients J Hypertens 19 2001 287 293
68. C. Zoccali, F. Mallamaci, and G. Tripepi Nocturnal hypoxemia predicts incident cardiovascular complications in dialysis patients J Am Soc Nephrol 13 2002 729 733
69. C. Zoccali, F. Mallamaci, and G. Tripepi Nocturnal hypoxemia: a neglected cardiovascular risk factor in end-stage renal disease? Blood Purif 20 2002 120 123
70. H. Tsuji, M.G. Larson, and F.L. Venditti Jr. Impact of reduced heart rate variability on risk for cardiac events. The Framingham Heart Study Circulation 94 11 1996 2850 2855
71. H. Fukuta, J. Hayano, and S. Ishihara Prognostic value of heart rate variability in patients with end-stage renal disease on chronic hemodialysis Nephrol Dial Transplant 18 2 2003 318 325
72. Chan CT, Hanly P, Gabor J, et al. Impact of nocturnal hemodialysis on the variability of heart rate and duration of hypoxemia during sleep. Kidney Int, in press.
73. A. Pierratos Daily nocturnal home hemodialysis Kidney Int 65 5 2004 1975 1986
74. P.E. Mohr, P.J. Neumann, and S.J. Franco The case for daily dialysis: its impact on costs and quality of life Am J Kidney Dis 37 4 2001 777 789
75. P.A. McFarlane, A. Pierratos, and D.A. Redelmeier Cost savings of home nocturnal versus conventional in-center hemodialysis Kidney Int 62 6 2002 2216 2222
76. C.M. Kjellstrand, R.L. Evans, and R.J. Petersen The " unphysiology" of dialysis: a major cause of dialysis side effects? Kidney Int Suppl 2 1975 30 34
77. C.T. Chan Nocturnal hemodialysis: an attempt to correct the "unphysiology" of conventional intermittent renal replacement therapy Clin Invest Med 25 2002 233 235